The Cobas EGFR Mutation Test v2 (Roche, Basel, Switzerland) is a diagnostic test for EGFR tyrosine kinase inhibitor therapies in NSCLC, while Guardant360 CDx (Guardant Health, Lansdale, PA, USA) and Liquid CDx (Foundation Medicine, Cambridge, MA, USA), analyzing the complete tumor genomic profile, help clinicians to understand responsiveness to checkpoint inhibitors and targeted therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.